(KTRA) – Company Press Releases
-
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
-
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
-
Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab
-
Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update
-
Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer
-
Kintara Therapeutics Announces Review of Strategic Alternatives
-
Kintara Therapeutics Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement
-
Kintara Therapeutics Announces Fiscal 2024 First Quarter Financial Results and Provides Corporate Update
-
Kintara Therapeutics Announces Preliminary Topline Results From GBM AGILE Study
-
Kintara Therapeutics to Present at the 8th Annual Dawson James Small Cap Growth Conference
-
Kintara Therapeutics to Present at the LD Micro Main Event XVI Conference
-
Kintara Therapeutics Presents Case Studies of Glioblastoma Patients Treated with VAL-083 at 2023 European Association for Neuro-Oncology Annual Meeting
-
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference
-
Kintara Therapeutics Announces Fiscal 2023 Year Financial Results and Provides Corporate Update
-
Kintara Therapeutics to Present at the 2023 European Association for Neuro-Oncology Annual Meeting
-
Kintara Therapeutics to Host Virtual KOL Event on VAL-083, A Potential First-in-Class Small Molecule Chemotherapeutic for Glioblastoma, on August 21, 2023
-
Kintara Therapeutics to Present at the Emerging Growth Conference
-
Presenting on the Emerging Growth Conference on August 9 & 10 Register Now
-
Kintara Therapeutics to Participate in the Fifth Annual Glioblastoma Awareness Day in Washington, D.C.
-
Kintara Therapeutics Awarded $2.0 Million National Institutes of Health SBIR Grant to Support the Clinical Development of REM-001
-
Kintara Therapeutics to Participate in the Maxim Group Virtual Healthcare Conference
-
Kintara Therapeutics to Commemorate National Brain Tumor Awareness Month with Ringing the Bell at Nasdaq Closing Along with Global Coalition for Adaptive Research and the National Brain Tumor Society
-
Kintara Therapeutics Announces Fiscal 2023 Third Quarter Financial Results and Provides Corporate Update
-
Kintara Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference
-
Kintara Therapeutics to Present at the Aegis Capital Virtual Conference
-
Kintara Therapeutics Announces Data Presentation at the 2023 American Association for Cancer Research Annual Meeting
-
Kintara Therapeutics to Present Two Posters at the 2023 American Association for Cancer Research Annual Meeting
-
Kintara Therapeutics Scheduled to Present at Two Conferences the Week of March 13, 2023
-
Kintara Therapeutics Announces Fiscal 2023 Second Quarter Financial Results and Provides Corporate Update
-
Kintara Therapeutics to Present at the 2023 BIO CEO & Investor Conference
-
Kintara Therapeutics to Present at the Biotech Showcase Conference on January 10, 2023
-
Kintara Therapeutics Receives Orphan Drug Designation for VAL-083 for Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)
-
Kintara Therapeutics to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022
-
Kintara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
-
Kintara Therapeutics Granted Fast Track Designation from FDA for REM-001 for Cutaneous Metastatic Breast Cancer
-
Kintara Therapeutics Presents Three Posters at the 2022 Society for Neuro-Oncology Annual Meeting
-
Kintara Announces One-for-Fifty Reverse Stock Split
-
Kintara Therapeutics Announces Fiscal 2023 First Quarter Financial Results and Provides Corporate Update
-
Kintara Therapeutics Pauses REM-001 Program to Conserve Funds to Support VAL-083 International Registrational Study
-
Kintara Therapeutics Announces Fiscal 2022 Financial Results and Provides Corporate Update
-
Kintara Therapeutics Announces Three Abstracts Have Been Accepted for the 2022 Society for Neuro-Oncology Annual Meeting
-
Kintara Therapeutics Receives Study May Proceed Letter from the FDA for REM-001 for Cutaneous Metastatic Breast Cancer
-
Kintara Therapeutics Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital
-
Kintara Therapeutics to Present at the Alliance Global Partners Summer Healthcare Conference
-
Kintara Therapeutics Granted Fast Track Designation from the FDA for VAL-083 for Newly-Diagnosed Glioblastoma
-
Kintara Therapeutics to Present at the JMP Securities Life Sciences Conference
-
Kintara Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement
-
Kintara Announces First European Site Activation in Switzerland in GCAR Phase 2/3 Clinical Trial for Glioblastoma
-
Kintara Therapeutics Announces Fiscal 2022 Third Quarter Financial Results and Provides Corporate Update
-
Kintara Therapeutics to Present at the Planet MicroCap Showcase 2022
Back to KTRA Stock Lookup
